A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium
Cancer Immunology, Immunotherapy · 25.02.2026 · 75 (3)
DOI: 10.1007/s00262-025-04288-6 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 25.02.2026. Verfasst von Takafumi Yanagisawa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan. t.yanagisawa.jikei@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Anilides, Quinolines, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan. t.yanagisawa.jikei@gmail.com.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. t.yanagisawa.jikei@gmail.com.
- Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Zitieren
APA
Yanagisawa, T., Mori, K., Kawada, T., Katayama, S., Tsujino, T., Maenosono, R., Toyoda, S., Nukaya, T., Morinaka, H., Tamura, K., Fukuokaya, W., Urabe, F., Murakami, M., Bekku, K., Takahara, K., Fujita, K., Azuma, H., Araki, M., Inamoto, T., …, & JK-FOOT study group (2026). A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium. Cancer Immunology, Immunotherapy, 75(3). https://doi.org/10.1007/s00262-025-04288-6
Vancouver
Yanagisawa T, Mori K, Kawada T, Katayama S, Tsujino T, Maenosono R, et al. A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium. Cancer Immunology, Immunotherapy. 2026;75(3). doi:10.1007/s00262-025-04288-6
BibTeX
@article{Yanagisawa2026,
author = {Yanagisawa, Takafumi and Mori, Keiichiro and Kawada, Tatsushi and Katayama, Satoshi and Tsujino, Takuya and Maenosono, Ryoichi and Toyoda, Shingo and Nukaya, Takuhisa and Morinaka, Hirofumi and Tamura, Keita and Fukuokaya, Wataru and Urabe, Fumihiko and Murakami, Masaya and Bekku, Kensuke and Takahara, Kiyoshi and Fujita, Kazutoshi and Azuma, Haruhito and Araki, Motoo and Inamoto, Teruo and Komura, Kazumasa and Kimura, Takahiro and JK-FOOT study group, JK-FOOT study group},
title = {A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
volume = {75},
number = {3},
doi = {10.1007/s00262-025-04288-6}
}
EUVIMED